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K  Trust i s  the key to extending harm reduction among injectors  (Finnish National  Publ ic Health Insti tute and Department of Infectious  Disease Epidemiology and
Control , 2008). Study of Finnish needle exchanges  and health counsel l ing centres  which substantia l ly informed the principles  adopted in European guidance:
“Trust seemed the most s igni ficant s ingle factor in the success  of health counsel l ing,” bui l t in the day-to-day contact between staff and a marginal ised,
stigmatised, and wary caseload.
K  Feel ing accepted and safe promotes  service access  (2011). Users  of Canadian needle exchanges  saw them as  safe place free of stigma, discrimination and
judgments  about drug use, and therefore places  where they could access  services  such as  counsel l ing, nurs ing care, HIV, hepati tis  C and sexual ly transmitted
infection testing and information, welfare services  and support, and housing. One of the Canadian studies  which informed the emphasis  on trust in a  review which
underpinned NICE guidance on needle exchange.
K  Counsel lors  di ffer in how wel l  they retain methadone patients  (1999). US study started off investigating methadone dose but found that when tai lored to the
individual  i t made no di fference. What did make a big di fference to retention and i l legal  substance use (the two were related) was  which counsel lor the patient had
(essentia l ly at random) been ass igned to. Retention on methadone is  (see cel l  A1) strongly related to harm reduction. This  study was one of three featured in this
Findings  analys is  (1999).
K  Constructive responses  from counsel lors  help keep methadone patients  in treatment (1998). Patients  stayed longer when their problems were constructively
responded to by their counsel lors  such as  by offering a  dose increase or extra services . Retention on methadone is  (see cel l  A1) strongly related to harm reduction.
This  study was one of three featured in this  Findings  analys is  (1999).
K  See cel l  B 3  for other methadone maintenance studies .
R  Extending harm reduction is  bui l t on trust (2013). Extens ive UK review updated in 2013 which underpinned NICE guidance on needle exchange found evidence
from Canada that “trusting relationships” between injectors  and exchange staff “appears  to be key to faci l i tating engagement in additional  harm reduction
services”.
R  See cel l  B 3  for methadone maintenance reviews.
G  European guidance on preventing infectious  diseases  among injectors  (European Centre for Disease Prevention and Control  and European Monitoring Centre for
Drugs  and Drug Addiction, 2011). Includes  des ired values  and atti tudes  of services  and staff, based partly on research from Finland.
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What is this cell about? As described more fully in the cell A1 bite, about reducing the harms experienced by the user as a result of their
drug use, without necessarily reducing use or seeking to overcome dependence. Common interventions include needle exchanges and
substituting a legally prescribed drug of the same type for the original (and usually illegally obtained) substance, also considered as a
treatment for addiction in row 3. This cell is however not about the content of the intervention (for which see cell A1), but whether its
impact depends on the interpersonal style and other features of the practitioner relating to the client or conducting the intervention – a
much less commonly researched topic.
Where should I start? European guidance exemplifies the contrast between what to staff, users and experts is the patent centrality of
the ‘right’ attitudes among harm reduction service staff, and the lack of research confirming these attitudes make the expected
difference. Where outcome evaluations were lacking, it drew instead on expert advice, best practices, and documented user preferences.
Largely on this basis, after consultation with experts and people involved in harm reduction across Europe, the report’s authors concluded
that “Obtaining the trust of the clients of the services is essential for the prevention of infectious diseases”. Take a look at the core
values section starting page 9 of the document, page 14 of the PDF file. There you will see that the “prevention principles” on which the
document is based themselves demand and rest on the ability and willingness of staff to centre their work on the needs, perspectives,
and vulnerabilities of what to the broader society are among its most despised and shunned members. So key are these attributes that
without them, no matter what the scientific and logical basis for interventions, they would be “difficult to apply effectively”. What are
these attributes? In essence, adopting a client perspective and earning the trust of the clients. In more detail, maintaining a user-friendly
atmosphere, “which means clients are addressed with dignity and a true willingness to help, whatever their appearance or social status
[and] client wishes are respected”. In turn that means “actively listening to the clients and responding to changing needs”, and a
pragmatic willingness to embrace objectives which to others may seem unacceptably short of ideal outcomes. That too entails an ability
to “refrain from ideological or moral judgment ... it is not helpful to judge or criticise [clients’ drug] use itself from a moral or ideological
point of view. Instead, the choices users make should be respected even if they are not agreed with”. Yet while non-judgmentally
respecting their clients’ choices, these same staff are also expected to use the trusted communication routes they have built to
encourage them (eg, through addiction treatment) to consider relinquishing injection and dependent substance use – a difficult balancing
act requiring exceptional relationship builders. On the basis of Canadian research, a UK review for NICE also agreed that extending harm
reduction beyond needle exchange depends on trust.
Issues to think about
 Sometimes the most important things cannot (readily) be proven. Regular ‘bite’ readers will have noticed that we have skipped the
‘Highlighted study’ section. This is because it seems no single study is significant enough to be highlighted, reflecting the relative
neglect of practitioner/relationship factors in harm reduction research, probably itself a function of the focus on interventions and the
difficulty of conducting such research. It is easier and less ethically dubious to randomly assign clients to different interventions, than it
is to deliberately assign some to judgemental, inflexible and hostile practitioners, and others to the best staff. It means that while there
is reason to strongly suspect that practitioner/relationship factors are crucial to achieving harm reduction outcomes, no study has yet
demonstrated this conclusively. As illustrated by the lack of randomised controlled trials of parachutes, some things which are
lifesavingly fundamental are not susceptible to this form of proof. Instead we have studies showing some methadone counsellors hold on
to patients longer and help them control their substance use much better than others, and that constructive rather than punitive
responses or neglect of patient problems are part of the reason. We can assume from other studies that these patients who stay longer
and inject less often should be relatively protected from harm. Similarly for needle exchanges, we know (eg, from Finland and Canada)
that users value the acceptance and caring they receive there, a contrast to the rejection and stigma they often feel from non-specialist
services, and that this makes them more open to seeking and accepting further help which should help reduce the harm they experience.
But “should” is not proof this has happened. It is not uncommon, for example, for patients to stay longer in treatment due to various
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reasons (eg, because this is their preferred option) yet for this to bear little relationship to the improvements service and patient are
seeking. But of all the major treatment modalities, this is least true for methadone programmes, which usually act much like a light
switch – rapid impact when switched on, rapid reversal when switched off. Less clear is whether the extra services exchange clients
might access in an atmosphere of trust do any more to (for example) intercept disease transmission than the basic needle exchange
service. But what seems unquestionable is that if users value them, then at least they are getting something out of the process, even if it
is not being measured by researchers and even if it is not particularly valued by the broader society.
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